动物造模,前列腺癌人源性异种移植裸鼠模型 z-bio 2021-11-11 648

　　Objective: How to establish a human-derived prostate cancer xenograft (PDX) model and evaluate the anti-tumor effects of various treatment options?

　　Method: Mix fresh human prostate cancer surgical specimens with Matrigel, and then transplant them into supplemented nude mice. The source androgen continuously monitors the growth of the subcutaneous tumor, evaluates its fidelity, and allows it to pass continuously. Tumor-bearing mice were divided into four groups: docetaxel group, castrate group and docetaxel combined castrate group. The mice were weighed during the treatment. After treatment, have you evaluated the effect of treatment by measuring total prostate specific antigen (tPSA) levels and serum histopathological changes?

　　Results: A PDX model of prostate cancer including hormone sensitivity (D17225) and castration resistance (C40019) was successfully established. Pathological analysis showed that the transplanted tumor was the main feature of the patient's primary tumor, and it was found that it could be maintained well; Pathology and serum tPSA test found that the castration group showed better therapeutic effect in the D17225 model, and the latter has a more obvious tumor suppressor effect. Do you have any?

　　Conclusion: The PDX model of prostate cancer has been successfully established and passaged stably. What is the therapeutic effect of hormone sensitivity (D17225) on the PDX model of prostate cancer?